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Abstract:
Neutrophils plays a crucial role in the intertwined processes of thrombosis and inflammation. Altered
neutrophil phenotype may contribute to inadequate resolution which is known to be a major
pathophysiological contributor of thrombo-inflammatory conditions such as Sickle Cell Disease (SCD). The
endogenous protein Annexin A1 (AnxA1) facilitates inflammation resolution via Formyl Peptide Receptors
(FPRs). We sought to comprehensively elucidate the functional significance of targeting neutrophil
dependent AnxA1/FPR2/ALX pathway in SCD. Administration of AnxA1 mimetic peptide AnxA1Ac2-26 ameliorated
cerebral thrombotic responses in Sickle transgenic mice via regulation of FPR2/ALX (a fundamental
receptor involved in resolution) pathway. We demonstrated direct evidence that neutrophils with SCD
phenotype play a key role in contributing to thrombo-inflammation. In addition, AnxA1Ac2-26 regulated
activated SCD neutrophils through protein kinase B (Akt) and extracellular signal-regulated kinases
(ERK1/2) to enable resolution. Herein, we present compelling conceptual evidence that targeting the
AnxA1/FPR2/ALX pathway may provide new therapeutic possibilities against thrombo-inflammatory conditions
such as SCD.
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Key Points:  43 
1. AnxA1Ac2-26 plays a key role in mitigating neutrophil-dependent thrombo-inflammatory 44 
responses in Sickle Cell Disease. 45 
2. Targeting the AnxA1/Fpr2/ALX pathway attenuates and protects against thrombo-46 
inflammatory events by switching the pathological neutrophil phenotype from a pro-47 
NETotic to pro-apoptotic, thereby driving resolution. 48 
  49 
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Abstract  50 
Neutrophils plays a crucial role in the intertwined processes of thrombosis and inflammation. 51 
Altered neutrophil phenotype may contribute to inadequate resolution which is known to be a 52 
major pathophysiological contributor of thrombo-inflammatory conditions such as Sickle Cell 53 
Disease (SCD). The endogenous protein Annexin A1 (AnxA1) facilitates inflammation resolution 54 
via Formyl Peptide Receptors (FPRs). We sought to comprehensively elucidate the functional 55 
significance of targeting neutrophil dependent AnxA1/FPR2/ALX pathway in SCD. 56 
Administration of AnxA1 mimetic peptide AnxA1Ac2-26 ameliorated cerebral thrombotic 57 
responses in Sickle transgenic mice via regulation of FPR2/ALX (a fundamental receptor 58 
involved in resolution) pathway. We demonstrated direct evidence that neutrophils with SCD 59 
phenotype play a key role in contributing to thrombo-inflammation. In addition, AnxA1Ac2-26 60 
regulated activated SCD neutrophils through protein kinase B (Akt) and extracellular signal-61 
regulated kinases (ERK1/2) to enable resolution.  Herein, we present compelling conceptual 62 
evidence that targeting the AnxA1/FPR2/ALX pathway may provide new therapeutic 63 
possibilities against thrombo-inflammatory conditions such as SCD. 64 




Neutrophils, the most abundant immune cells (contributing to 60-70% of the leukocyte 67 
population) and one of the most important effector cells of the immune system, play crucial roles 68 
in inflammation resolution. Inflammation is interconnected with thrombosis, with one begetting 69 
the other, leading to a pro-thrombo-inflammatory state
1,2
 that is associated with a number of 70 






 These chronic thrombo-71 
inflammatory diseases often result in severe acute cardiovascular complications (acute ischemic 72 
stroke [AIS], pulmonary embolism and microvascular angiopathies
6
) which are the most frequent 73 




Sickle Cell Disease (SCD) is an inherited autosomal recessive disorder resulting from a single 76 
amino acid substitution in the hemoglobin β chain.
8
 The pathophysiology of SCD is characterized 77 
by a relentless pro-thrombo-inflammatory state, which enables a heightened propensity for 78 
ischemic events such as AIS. Despite these patients being more susceptible to ischemic events 79 
and having poorer outcome post-AIS, the mechanisms remain poorly understood. However, these 80 
detrimental effects may be caused by inadequate class switching of endogenous pro-resolving 81 
mediators.
9,10
  Thus, SCD provides a unique model to study a defective resolution process to 82 





Under homeostatic conditions, inflammation resolution is orchestrated by a tightly controlled 86 
series of endogenous biosynthetic mediators (e.g. Annexin A1 [AnxA1] and its biologically 87 
active N-terminal domain, peptide AnxA1Ac2-26,
13





 and protective pro-resolution pathways (e.g. formyl peptide receptor-[FPR]-89 
pathway),
15
 However, these endogenous biosynthetic circuits may be hampered in chronic 90 
thrombo-inflammatory diseases. Both AnxA1 and AnxA1Ac2-26 are known to exert their anti-91 
inflammatory and pro-resolving actions in acute and chronic inflammation by engaging with 92 
FPR2/ALX.
13,15,16
 Thus, exploring AnxA1/FPR2/ALX pathways in disease states characterized 93 
by chronic uncontrolled thrombo-inflammation, may provide a viable therapeutic strategy to 94 
promote resolution, affording protection. 95 
 96 
Using genetic and pharmacological approaches, along with clinical samples, we present novel 97 
and compelling data that AnxA1Ac2-26 plays a key role in mitigating neutrophil-dependent 98 
thrombo-inflammatory responses in the cerebral microvasculature via AnxA1/FPR2/ALX 99 
pathway. Furthermore, we demonstrate that exogenous administration of AnxA1Ac2-26 regulates 100 
pro-thrombotic neutrophil responses without affecting physiological responses, through protein 101 
kinase B (Akt) and extracellular signal-regulated kinases (ERK1/2),
17,18
 which act as molecular 102 
switches to transform the  neutrophil phenotype from a pro-NETotic to pro-apoptotic phenotype 103 
thereby driving resolution. These compelling data demonstrate the propensity for therapeutic 104 
strategies based on Resolution Biologics for the management of thrombo-inflammatory 105 
complications.  106 
 107 
Material and Methods  108 
See Online Supplement for in-depth methods. 109 
 110 
Drugs, reagents and antibodies 111 
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For in-vivo experiments, vehicle (saline), Annexin A1 (AnxA1) mimetic peptide Ac2-26 112 
(AnxA1Ac2-26, Ac-AMVSEFLKQAWFIENEEQEYVQTVK, Cambridge Research Biochemicals) 113 
100 µg/mouse,
19
 Boc2 (N-tert-butoxycarbonyl-L-Phe-D-Leu-L-Phe-D-Leu-L-Phe, MP 114 
Biomedicals, Cambridge, UK) 10 µg/mouse,
19
 and WRW4 (55 μg/mouse) (EMD Biosciences 115 
Inc) were administered (100 µl) intravenously (i.v.) at the start of cerebral reperfusion.
20
  116 
 117 
For in-vitro experiments, vehicle 1X Phosphate buffered saline (PBS) (Life Technologies) 118 
AnxA1Ac2-26 (30 µM), Boc2 (10 µM),WRW4 (10 µM),
21
 Akti-1/2 (10 µM),
18
 U0126 (10 µM) 119 
(Tocris), Caspase-3 inhibitor Z-DEVD-FMK (20 µM) (R&D systems, Minneapolis, MN, USA) 120 
were used as pharmacological tools NETs were induced by ionomycin (4 µM) (Life 121 
Technologies). NET specific stains include neutrophil elastase rabbit anti-NE (1:200) (Abcam), 122 




Animals  125 
Male control and Sickle Cell Transgenic mice (STM. Townes) (Homozygous at the Hba locus for 126 
the hα mutation [Hba
tm1(HBA)Tow
] and homozygous at the Hbb locus for the -383 γ-β
A
 mutation 127 
[Hbb
tm3(HBG1,HBB)Tow
]) were purchased from Jackson Laboratory (Bar Harbor). Animal Care and 128 
Use Committee of LSUHSC-S approved experimental procedures performed on the mice. All 129 
studies were performed blinded and randomized and all studies complied with ARRIVE (Animal 130 
Research: Reporting In Vivo Experiments) guidelines. 131 
 132 
Human samples  133 
The study was approved by the institutional review board of the LSUHSC-S (STUDY00000572 134 
and STUDY00000261) and conducted in accordance with the Declaration of Helsinki. After 135 
signed consent was obtained, blood was taken from control volunteers (18-52 years old, twenty-136 
six males, eighteen females) and SCD patients (18-52 years old, nineteen males, twenty-eight 137 
females). All but one of the SCD patients were of HbSS (homozygous hemoglobin S) genotype. 138 
One patient was HbSC (sickle hemoglobin C disease) genotype. SCD patients were recruited 139 
upon routine clinical visits at the Feist-Weiller Cancer Center at LSUHSC-S. All SCD patients 140 
were on chronic hydroxyurea therapy and blood was obtained just before exchange transfusion. 141 
Hydroxyurea was started at 15 mg per kilogram of body weight per day and then escalated by 5 142 
mg per kilogram every 12 weeks until the maximum tolerated dose was achieved on the basis of 143 
peripheral blood counts. Patients were on partial exchange transfusion every two weeks. Patients 144 
with acute infection or other chronic blood borne diseases (HIV, Hepatitis B/C) were excluded 145 
from the study. Demographic and clinical characteristics of controls and SCD patients are 146 




Neutrophil depletion and DNase I treatment 149 
Neutropenia was induced using mouse anti-neutrophil serum (ANS; 1A8. 150 μg/mouse, 150 
intraperitoneally 24 hours before the experiment).
22
 DNase I (2000U) was administered i.v for 151 
NET degradation. 152 
 153 
Thrombosis  154 
Anesthetized mice (Ketamine: Xylazine, 1:1) were kept under the microscope after jugular vein 155 
cannulation and open window craniotomy. Thrombosis in cerebral vessels was induced using the 156 
light/dye thrombosis model.
23
 After 20 minutes of equilibration, 10 mg/kl of 5% FITC-dextran 157 
(150 000 MW) (Sigma-Aldrich) was injected via the femoral vein and allowed to circulate for 10 158 
minutes. Photoactivation was initiated (excitation, 495 nm; emission, 519 nm) by exposing 100 159 
μm of vessel length to epi-illumination with a 175-W xenon lamp (Lamda LS; Sutter) and a 160 
fluorescein filter cube (HQ-FITC; Chroma). Time was recorded when the platelet aggregates first 161 
start appearing (onset time) and the time when flow stops for 30 seconds (cessation time).  30 162 
minutes prior to onset of thrombosis, mice were treated with vehicle, AnxA1Ac2-26 (100 163 
µg/mouse), Boc2 (10 µg/mouse), or WRW4 (55 μg/mouse).  164 
 165 
ELISA for NETs  166 
To quantify the NETs in the circulating blood, 96 well immunoassay plates (#9018, Costar) were 167 
coated with a neutrophil elastase antibody (1:250, Abcam) in 15 mM of Na2CO3, at pH 9.6 (250 168 
μl per well) overnight at 4°C. The following day wells were washed three times with PBS, 169 
followed by blocking with 5% BSA for two hours at room temperature. After blocking, the wells 170 
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were washed again (three times) with PBS. 50 μl of murine plasma was added to the wells and 171 
incubated for two hours at room temperature and kept on a microplate shaker at 250 rpm. The 172 
plates were then washed (three times) with wash buffer (1% BSA, 0.05% Tween 20 in PBS). This 173 
was followed by incubation with the immunoreagent (100 μl in each well). The immunoreagent 174 
was prepared by mixing 1/20 volume of anti-DNA-Peroxidase conjugated antibody (Anti-DNA-175 
POD) with 19/20 volumes incubation buffer (Cell Death Detection ELISA
PLUS
, Roche) for two 176 
hours at room temperature and kept on a microplate shaker at 250 rpm. The solution was 177 
removed, and each well was rinsed three times with 250 μl of incubation buffer. Next, 100 μl of 178 
2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS, Roche) was added and the plate 179 
was incubated for 10-20 minutes on a microplate shaker at 250 rpm. The reaction was stopped by 180 
pipetting 100 μl of ABST stop solution (ROCHE) and the absorbance was measured at 405 nm 181 
plate reader (Synergy H1, BioTek) (reference wavelength approx. 490 nm). Data was analyzed as 182 
per the manufacturer’s instructions (Roche). 183 
 184 
Murine neutrophil isolation and adoptive transfer 185 
Murine neutrophils were isolated, kept at 5x10
6
/ml and treated with AnxA1Ac2-26 (30µM), 186 
WRW4 (10μM) or AnxA1Ac2-26+WRW4 for 10 minutes prior to injection (5x10
5
 cells per 187 
mouse) via the jugular vein of the recipient neutropenic mouse. 188 
 189 
Isolation of human neutrophils  190 
Neutrophils were isolated from control donors and SCD patients using dextran (spectrum 191 






Visualization and quantification of NETs 194 
Neutrophils (1x10
5
/well) were seeded on poly-l-lysine coated coverslips and were stimulated for 195 
3hours at 37oC, 5% CO2. The cells were fixed (10% formalin), permeabilized (0.5% Triton X-196 
100), blocked (10% goat serum) and incubated with NET specific antibodies (neutrophil elastase 197 
rabbit anti-NE [1:200], histone H3 mouse anti-H3Cit [1:200]) and species-specific secondary 198 
antibodies, and visualized. 199 
 200 
Annexin A1 quantification in plasma 201 
Human and murine AnxA1 ELISA kits (MyBioSource) were used to quantify the plasma levels 202 
of AnxA1. Plasma preparation and the ELISA assay were done according to manufacturer’s 203 
instructions. Results were reported as ng/ml of AnxA1 concentration in plasma of control 204 
volunteers and SCD patients or in plasma of control and STM mice.   205 
 206 
Western blotting 207 
Samples were immunoblotted with rabbit anti-phospho-Akt1 (1:1000), goat anti-Akt1 (1:500), 208 
rabbit anti-phospho-ERK1/2 (1:1000), or rabbit anti-ERK1/2 (1:5000) antibodies overnight 209 




Cleaved caspase-3 for apoptotic cells 212 
Neutrophils (2x10
5
/well) were seeded on poly-l-lysine coated coverslips and treated with 1X PBS 213 
or AnxA1Ac2-26 (30µM) (3hours, 37°C, 5% CO2). Cells were incubated with caspase-3 214 




Myeloperoxidase release assay (MPO)  217 
Neutrophils (1x10
5
/well) were left unstimulated, ionomycin-stimulated (4M), or pre-treated 218 
with AnxA1Ac2-26 (30 µM) 15minutes prior pre-stimulation (3 hours at 37
o
C, 5% CO2). After 219 
3hours, supernatant was collected, added to MPO solution, reaction terminated with H2SO4(2N) 220 
and  absorbance read (450nm).  221 
 222 
Chemotaxis assay  223 
Human neutrophils tagged with Calcein-AM (Invitrogen) were left unstimulated, ionomycin-224 
stimulated (4 M), or pre-treated with AnxA1Ac2-26 (30 µM) 15 minutes prior pre-stimulation. 225 
Neutrophils were added to ChemoTx® System. After 3 hours fluorescence intensity was 226 
measured (485/530nm excitation/emission) to determine neutrophil chemotaxis towards LTB4 227 
(10
-6
 M) or PBS (control).  228 
 229 
Quantification of Interleukin 1 beta (IL-1) ELISA 230 
Human neutrophils were left unstimulated, ionomycin-stimulated (4 M), or pre-treated with 231 









For original data, please contact felicity.gavins@brunel.ac.uk 236 
 237 
Statistical Analysis  238 
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All data was tested to follow a normal distribution using Kolmogorov-Smirnov test of normality 239 
with Dallal-Wilkinson-Lillie D’Agostino-Pearson omnibus normality test for corrected p value. 240 
Data that passed the normality assumption was analyzed using Student’s t-test (two groups) or 241 
ANOVA with Bonferroni post-tests (more than two groups). Data that failed the normality 242 
assumption were analyzed using the non-parametric Mann-Whitney U test (two groups) or 243 
Kruskal-Wallis with Dunn’s test (more than two groups). Analysis was performed using Graph 244 
Pad Prism 6 software (San Diego). Data are shown as mean values ± standard error of the mean 245 
(SEM). Outliers were defined as ≥ two standard deviations and have been stated in the figure 246 
legends where necessary. Differences were considered statistically significant at a value of p < 247 
0.05. 248 
  249 
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Results  250 
AnxA1Ac2-26 ameliorates exacerbated cerebral thrombosis in SCD via Fpr2/ALX  251 
Thrombo-inflammatory disease states such as SCD are often associated with a microcirculation 252 
that assumes a pro-inflammatory and pro-thrombotic state.
26
 To validate our experimental model 253 
of thrombo-inflammation, we performed a light/dye injury model
23
 (enabling visualization of 254 
thrombus formation in real-time [Videos 1+2]) and observed accelerated thrombus formation 255 
(decrease in blood flow cessation time) in both cerebral arterioles (p<0.0001) and venules 256 
(p<0.01) of STM vs. control mice (Figure 1A-F), concurring with our previous findings in a non-257 




AnxA1 and its mimetic peptides (e.g. AnxA1Ac2-26) are recognized anti-inflammatory compounds 260 
that have shown therapeutic potential in a diverse range of disease models including e.g. ischemia 261 
reperfusion induced lung injury, acute colitis, renal transplantation, diabetic nephropathy, 262 
atherosclerosis, acute lung injury and colitis.
27
 However their effects on thrombosis remain fairly 263 
unknown, although we have recently shown their attenuation of platelet responses.
16
 Here, Figure 264 
1E+F shows AnxA1Ac2-26 had no effect on cerebral thrombosis when exogenously administered 265 
to control mice, but significantly increased decreased blood flow cessation time in cerebral 266 
arterioles (p<0.001) and venules (p<0.01) of STM mice.  267 
 268 
Having established the anti-thrombotic effect of AnxA1Ac2-26  in STM, we next tested whether 269 
these effects were mediated via an interaction with the FPR-pathway (especially FPR2/ALX, 270 
which is a key receptor involved in resolution and a receptor through which AnxA1 mediates its 271 
effects). Figure 1E+F shows the FPR pan-antagonist Boc2 blocked the protective actions of 272 
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AnxA1Ac2-26 (p<0.001), suggesting a mechanism of action via the FPR family. To further tease 273 
out which receptor, mice were co-administered AnxA1Ac2-26+WRW4 (specific FPR2/ALX 274 
antagonist). WRW4 blocked AnxA1Ac2-26 afforded protection in both cerebral arterioles 275 
(p<0.001) and venules (p<0.001) thereby confirming an FPR2/ALX mechanism (Figure 1E+F).  276 
 277 
Neutrophils contribute to cerebral thrombosis in STM   278 
Compelling evidence exists demonstrating a pivotal role of neutrophils in thrombo-279 
inflammation
28
 although the role they play in context of cerebral thrombosis is less well 280 
discerned. To address this knowledge-gap we rendered STM mice neutropenic with the well-281 
characterized anti-neutrophil serum (ANS), 1A8. Using real-time live imaging, we observed a 282 
phenotype reversal i.e. no difference in cerebral thrombosis formation between control vs. 283 
STM/ANS mice (Figure 2B+C), demonstrating that the cerebral microvasculature in STM mice 284 
was rendered vulnerable to thrombus formation via a neutrophil-dependent mechanism. 285 
Furthermore, adoptive transfer of STM, but not control, neutrophils into neutropenic STM mice 286 
(Figure 2A) restored the SCD-associated acceleration of thrombus formation in cerebral pial 287 
vessels (Figure 2B+C). These results suggest that the STM neutrophil plays a key role in 288 
mediating the accelerated cerebral thrombus formation observed in this experimental thrombo-289 
inflammatory model. 290 
 291 
AnxA1Ac2-26 inhibits the thrombotic NET phenotype associated with thrombo-inflammation  292 
Having discovered neutrophils play a significant role in cerebral thrombosis and exploiting the 293 
fact that AnxA1/FPR2/ALX pathway can mitigate these unwanted responses, we next 294 
characterized the mechanisms involved in this process. NET formation is associated with the 295 
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pathogenesis of several thrombo-inflammatory diseases e.g. in thrombi associated with deep-vein 296 
thrombosis and detected via histology in the lungs of SCD mice.
29
 Here, administration of  297 
DNase (which breaks down NETs) delayed blood flow cessation in STM mice, an effect absent in 298 
control mice (Figure 2D).  299 
No differences in circulating AnxA1 plasma levels in control vs. STM were quantified (Figure 300 
2E), but treatment of control and STM mice with AnxA1Ac2-26 resulted in significant reduction of 301 
neutrophil elastase (NE-DNA) complexes in STM but not control plasma (p<0.05) (Figure 2F) 302 
suggesting an anti-thrombotic mechanism and elucidating a drug-sparing effect in normal 303 
cohorts.   304 
 305 
To test whether AnxA1Ac2-26 anti-thrombotic effect in-vivo occurs by reducing the capability of 306 
neutrophils to release NETs (known contributors to thrombosis),
30
  isolated neutrophils (control 307 
and STM mice) were treated with the NET-inducing stimuli ionomycin (a natural calcium 308 
ionophore) to stimulate maximal NET production with and without AnxA1Ac2-26. Citrullinated 309 
histone-3 (H3Cit) is the most common NET biomarker that has been associated with 310 
experimental thrombosis.
31
 Figure 2G shows AnxA1Ac2-26 treatment significantly reduced the 311 
percentage of ionomycin-stimulated STM neutrophils that were positive for H3Cit
+
 (p<0.05), an 312 
effect not observed in control neutrophils, further emphasizing the specific effect of AnxA1Ac2-26 313 
on neutrophils exposed to a chronic thrombo-inflammatory milieu associated with SCD.  314 
 315 
Targeting Fpr2/ALX reduces human H3Cit
+ 
SCD neutrophils without affecting 316 
physiological responses 317 
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To translate our findings from mouse models into clinical setting, we isolated neutrophils from 318 
control volunteers and SCD patients (Figure 3A+B). The percentage of unstimulated H3Cit
+
SCD 319 
neutrophils was increased compared to control neutrophils (Figure 3C), which was further 320 
exacerbated with ionomycin (p<0.05), suggesting SCD neutrophils are characterized by extensive 321 
histone citrullination potentially contributing to the pro-thrombotic phenotype. Interestingly, our 322 
SCD patients presented with reduced circulating AnxA1 plasma levels versus control volunteers, 323 
highlighting a possible defect in the resolution process as is often seen in chronic thrombo-324 
inflammatory states (Figure 3D). Moreover, as observed with murine neutrophils AnxA1Ac2-26 325 
significantly attenuated ionomycin-induced H3Cit
+
 SCD neutrophils (p<0.0001) (Figure 3E) (no 326 
effect was observed in control volunteers). Finally, to determine the mechanistic role of FPR-327 
family in these events, FPR pan-antagonist Boc2 was co-administered with AnxA1Ac2-26. Figure 328 
3E shows Boc2 significantly abrogated AnxA1Ac2-26 effects, increasing H3Cit
+ 
SCD neutrophil 329 
percentage (p<0.05). More specifically, when co-administered with AnxA1Ac2-26, the selective 330 
Fpr2/ALX antagonist WRW4 increased the percentage of H3Cit
+ 
SCD neutrophils, thus 331 
abrogating the protective actions of AnxA1Ac2-26. These results highlight the protective effects of 332 
AnxA1Ac2-26 on NET production were mediated through Fpr2/ALX. 333 
 334 
Interestingly, although AnxA1Ac2-26 modulated histone citrullination under pro-NETotic 335 
conditions, the resolving peptide did not affect other neutrophil physiological responses such as 336 
MPO release and chemotaxis (Supplementary Figure 2A-C). This lack of effect could be due to 337 
the fact that under pro-NETotic conditions, neutrophils are in point of no return releasing their 338 
MPO following membrane disruption. Furthermore, although IL-1 production was increased in 339 
unstimulated SCD neutrophils compared to control, it was dramatically reduced when neutrophils 340 
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were stimulated with ionomycin, with AnxA1Ac2-26 having no effect (Supplementary Figure 2D). 341 
These effects may be due to the ability of ionomycin-induced NETs to produce IL-1 degrading 342 
serine proteases.
32
  343 
 344 
AnxA1Ac2-26 regulates the NETosis-apoptosis axis in human SCD neutrophils: Impact for 345 
therapeutic strategy against thrombosis 346 
Due to importance of ERK and Akt kinases in NET release 
17,18,33
 we examined the expression of 347 
these kinases in control and SCD neutrophils (Figures 4A). A significant increase in ERK 348 
phosphorylation (at 15 minutes, p<0.001 respectively) and Akt phosphorylation (30 and 60 349 
minutes. p<0.01 each) was observed in ionomycin-stimulated SCD neutrophils vs. SCD 350 
neutrophils at baseline (Figures 4B-E) with no differences observed in baseline ERK and Akt 351 
phosphorylation in SCD patients and control volunteers (Figure 4B-E). Treatment of SCD 352 
neutrophils with AnxA1Ac2-26 showed an 85% reduction in ionomycin-induced ERK 353 
phosphorylation at 15 minutes (p<0.001 vs. ionomycin-stimulated control neutrophils at 15 354 
minutes) and approximately 75% reduction in ionomycin-induced Akt phosphorylation (30 and 355 
60 minutes. p<0.01 at each time point) compared to ionomycin-stimulated control neutrophils 356 
(Figures 4B-E). Furthermore, as with AnxA1Ac2-26 treatment, administration of Akt or Erk 357 
inhibitors reduced ionomycin-induced H3Cit
+
SCD neutrophils (Figure 4F). Interestingly, in the 358 
presence of Z-DEVD-FMK (caspase-3 inhibitor), AnxA1Ac2-26 no longer reduced the percentage 359 
of H3Cit
+
 neutrophils (Figure 4G), but treatment with AnxA1Ac2-26 alone increased cleaved 360 
caspase-3 (Figures 4H+I). Collectively, these data suggest a potential molecular mechanism by 361 






Using pharmacological and genetic approaches, coupled with murine and clinical samples we 366 
discovered several key conceptual and novel findings that we believe advances knowledge and 367 
understanding in the field of SCD, thrombo-inflammation and Resolution Biology. Specifically, 368 
we found: i) neutrophils from SCD, a known model of thrombo-inflammation,  play a major role 369 
in cerebral thrombosis; ii) targeting the Fpr2/ALX (a key receptor of inflammation resolution) 370 
mitigates these effects; iii) pro-resolving, anti-inflammatory mediator AnxA1Ac2-26 reduces 371 
H3Cit
+
 rich NET production, transforming neutrophil phenotype from pro-NETotic to pro-372 
apoptotic thereby driving thrombo-inflammation resolution in SCD (Figure 5).  373 
 374 
Using an experimental model of thrombo-inflammation, i.e. the Townes (STM) mouse (which 375 
recapitulates many clinical manifestations of SCD), we revealed heightened cerebral thrombotic 376 
responses. By exploiting the Fpr-pathway as a therapeutic target, administration of AnxA1Ac2-26 377 
resulted in blood flow prolongation in the cerebral microcirculation of STM (no change was 378 
observed in circulating neutrophil counts [Supplementary Table 1]) with effects being equally 379 
robust in both cerebral venules and arterioles (despite clear differences between vessel types, e.g. 380 
shear rates and leukocyte-endothelial interactions).
34
 These results demonstrate the potent activity 381 
and versatility of the AnxA1Ac2-26 to mitigate SCD associated thrombo-inflammation.  382 
 383 
Three FPRs exist in the humans: FPR1, FPR2/lipoxin A4 (Fpr2/ALX, orthologue in the mouse) 384 
and FPR3 
13
. Co-administration of AnxA1Ac2-26 with Fpr pan-antagonist Boc2 elicited an 385 
abrogation of the peptide’s protective responses. Moreover, this effect was consistent when the 386 
Fpr2/ALX-specific antagonist WRW4 was used, confirming not only the involvement of the Fpr-387 
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family in mediating the effects of AnxA1Ac2-26, but more specifically Fpr2/ALX. These findings 388 
are the first to show the protective effects of AnxA1Ac2-26 in cerebral thrombosis, demonstrating 389 
that AnxA1Ac2-26 not only possesses anti-inflammatory capabilities (e.g. attenuation of leukocyte-390 
platelet responses post stroke, reduction of lipopolysaccharide-induced leukocyte adhesion and 391 
migration), but holds anti-thrombotic capabilities, making it a promising therapeutic candidate for 392 
promoting resolution in the context of thrombo-inflammatory diseases such as SCD.  393 
 394 
Under normal physiological conditions, the host produces an adequate resolution response to 395 
inflammation and coagulation, characterized by specific immunoresolvents that induce clearance 396 
mechanisms e.g. apoptosis and efferocytosis.
10,16,35
 However, if the resolution process is 397 
defective, as observed in chronic thrombo-inflammatory states,
11,36
 then this results in the 398 
reduction/altered production of pro-resolving mediators as demonstrated by e.g. our SCD patients 399 
presented with having reduced circulating AnxA1 plasma levels versus control volunteers. 400 
(Supplementary Figure 3A+B). We speculate that this chronic deficit contributes to a non-401 
resolving state of inflammation, as previously observed.
16
 Interestingly, AnxA1 plasma levels in 402 
STM mice were similar to control mice.
11
 Although AnxA1 distribution is similar between 403 
human and murine neutrophils,
37
 differences in AnxA1 levels between species could be due to 404 
variances in neutrophil populations (e.g. human neutrophils constitute 65-75% of all peripheral 405 
blood leukocytes, unlike in the mouse, where ~10-25% of all leukocytes are neutrophils). 406 
Additionally, it was recently shown that resolvin (Rv)D1 (another endogenous pro-resolving 407 
mediator) levels were similar between SCD mice vs. controls. However lower levels of RvD1 408 
were detected in spleens (a known target of acute vasoocclusive crises) of SCD mice vs. controls 409 
under normoxia or when exposed to hypoxia/reoxygenation,
11
 suggesting like AnxA1, other 410 
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endogenous mediators may play important roles in thrombo-inflammation resolution. As 411 
observed in the clinic, STM mice presented with neutrophilia (Supplementary Table 2) and 412 
exhibited profound protection against microvascular thrombosis when made neutropenic. 413 
Furthermore, upon adoptive transfer of donor STM neutrophils into recipient controls, animals 414 
displayed a phenotype similar to that of the full STM mouse, highlighting a key role that 415 
circulating STM neutrophils play in mediating cerebral thrombosis, which may translate to the 416 
clinical setting.  417 
 418 
NET release results in circulating cf-DNA production, which is significantly increased in 419 
thrombo-inflammatory diseases, with detrimental effects.
38
 Here we discovered increased cfDNA 420 
in STM plasma was complexed with NE, which AnxA1Ac2-26 was able to reduce, possibly by 421 
blocking the attachment of elastase to chromatin in the neutrophil. In-vivo, DNase I (main factor 422 
regulating elimination of the cfDNA) heightened blood flow cessation times in STM mice, 423 
supporting the important role that NETs play in a thrombo-inflammatory environment. Our 424 
results suggest a distinctive NETotic phenotype exists in STM and AnxA1Ac2-26 specifically 425 
targets and reduces excessive NETosis in this thrombo-inflammatory model. 426 
 427 
Different studies on thrombosis as well as other inflammatory models including SCD have shown 428 
the importance of NET-associated citrullinated histone H3.
29,30
 Additionally, histones comprise 429 
65% of the total protein content in neutrophils and extracellular histones (which are the backbone 430 
of NETs) are known to participate in immunothrombosis due to their pro-thrombotic,
39
 pro-431 
inflammatory and cytotoxic effects.
40
 We demonstrated herein that AnxA1Ac2-26 was able to 432 
significantly modify both the pro-thrombotic STM- and the SCD-NET phenotype by suppressing 433 
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the production of citrullinated histone-rich NETs in an AnxA1/FPR2/ALX dependent 434 
mechanism. Additionally, the extracellular DNA production was not affected by AnxA1Ac2-26 435 
suggesting that the peptide does not reduce physiological netosis.
17,41
 These results are in 436 
accordance with our in-vivo data and may help to further explain the anti-thrombotic action of 437 
AnxA1Ac2-26. Although we observed some differences in findings from murine neutrophils vs. 438 
those with human neutrophils (e.g. NETs released from mice are more compact than those 439 
observed from humans),
42
 AnxA1Ac2-26 was still effective at specifically reducing histone-rich 440 
NET production. Interestingly, the effects of AnxA1Ac2-26 on H3cit
+
 neutrophils were only 441 
observed in STM and SCD neutrophils and not control neutrophils, suggesting that AnxA1Ac2-26 442 
spares physiological NETosis. Furthermore, our data shows that once AnxA1Ac2-26 is involved in 443 
regulating NET formation, it does not affect other neutrophil functions such as MPO release, 444 
chemotaxis or cytokine (IL-1) production but promotes resolution by changing the SCD 445 
neutrophil phenotype from a pro-NETotic to pro-apoptotic phenotype.  446 
 447 
There is paucity in studies on the cellular mechanisms by which AnxA1/FPR2/ALX can be 448 
channelled as an anti-inflammatory/pro-resolving pathway. We further discovered that SCD 449 
neutrophils displayed increased ERK and Akt (the main driver of NADPH-independent NET 450 
production)
41,43
  activation, ensuing in extensive histone citrullination as indicated by NET-based 451 
assays.
41
 AnxA1Ac2-26 inhibited ERK and Akt activity in SCD neutrophils, with inhibitors of ERK 452 
and Akt suppressing H3Cit
+
 neutrophil production to similar levels as those with AnxA1Ac2-26 453 
treatment. These data demonstrate a molecular mechanism by which AnxA1Ac2-26 is able to 454 
switch off the pro-thrombotic H3Cit
+
 NETotic drive and enhance the resolution.
35
 More 455 
importantly AnxA1Ac2-26 suppression of ERK and Akt phosphorylation was absent in control 456 
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neutrophils. These disparate effects of AnxA1Ac2-26 on SCD vs. control phenotype may point 457 
towards the configurational plasticity of the FPR signalling axis in response to biased agonism.
44
 458 
We also discovered AnxA1Ac2-26 to activate cleaved caspase-3 in SCD neutrophils, an effect that 459 
was abrogated in the presence of the specific caspase-3 inhibitor (Z-DEVD-FMK). Interestingly, 460 
these effects of AnxA1Ac2-26 on neutrophil apoptosis are also observed in an acute inflammation 461 
model of LPS-induced pleurisy.
45
 Taken together, our data provide a previously unknown 462 
phenomenon regarding the ability of AnxA1Ac2-26 to act as a natural homeostatic clearance ligand 463 
during an ensuing thrombotic process.  464 
 465 
In summary, our study provides substantial evidence that targeting the AnxA1-FPR2/ALX 466 
pathway may provide a viable strategy for the management of thrombotic complications 467 
associated with SCD. More specifically, from an intravascular perspective targeting SCD 468 
neutrophils via AnxA1-FPR2/ALX pathway reduces H3Cit
+
 NETotic drive which plays a key 469 
role (directly or indirectly) in preventing the activation of various downstream processes 470 
including platelet aggregation, thereby enabling and promoting resolution. These unique findings 471 
may provide impetus to the drug discovery programs based on Resolution Biologics in the 472 
management for not only SCD, but also other disease states with an underlying thrombo-473 
inflammatory phenotype. 474 
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Figure Legends 603 
Figure 1. AnxA1Ac2-26 rescues enhanced cerebral thrombus formation 604 
STM and control mice were subjected to light/dye-induced thrombosis with intravenous infusion 605 
of 10mg/kg 5% FITC-dextran followed by photoactivation of cerebral microvessels. (A-D) 606 
Images of onset (start of platelet aggregation) and cessation (complete stop of flow for 607 
≥30seconds) of thrombus formation in control and STM mice (scale bar=20μm). Mice were 608 
treated with Vehicle (saline), AnxA1Ac2-26 (100μg/mouse), AnxA1Ac2-26+Boc2 609 
(100μg/mouse+10μg/mouse) or AnxA1Ac2-26+WRW4 (100μg/mouse+55μg/mouse), subjected to 610 
light/dye-induced thrombosis and time of flow cessation (minutes) was quantified in cerebral (E) 611 













p<0.001 vs. STM+AnxA1Ac2-613 
26 treated. 614 
 615 
Figure 2. Neutrophils contribute to cerebral thrombosis in experimental thrombo-616 
inflammation and exhibit enhanced extracellular DNA activity 617 
Schematic representation of adoptive neutrophil transfer from donor control and STM into 618 
neutropenic (anti-neutrophil serum [ANS]) recipient STM followed by light/dye-induced 619 
thrombosis (A1-3) time of flow cessation was quantified in cerebral (B) arterioles and (C) 620 
venules. (D) Cerebral microvessels were analyzed following DNase (2000U) treatment (n=4-621 
6mice/group).  622 
(E) Plasma levels of circulating Annexin A1 (n=6 each) were also determined in control mice and 623 
STM. (F) Neutrophil elastase DNA complex (NE-DNA) levels were determined by ELISA in 624 
plasma from saline (vehicle) and AnxA1Ac2-26-treated mice (n=12 saline and n=6 AnxA1Ac2-26 625 
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treated control and STM [Two values for control-AnxA1Ac2-26 and one value STM-AnxA1Ac2-26 626 
were under detectable levels and not included]). (G) percentage histone H3 (H3Cit
+
) positive 627 
unstimulated (n=10 [one outlier removed]. n=10 STM [one outlier removed]) and ionomycin-628 
stimulated (n=10 control, n=7 STM. [4µM]) neutrophils. Data shown as mean±SEM from 629 
independent experiments. 
*




p<0.001 vs. STM, 
@@
p<0.01 vs. 630 
unstimulated STM neutrophils and 
$
p<0.05 vs. stimulated STM neutrophils. 631 
 632 
Figure 3. SCD-associated enhanced H3Cit
+
 neutrophils can be inhibited by AnxA1Ac2-26 633 
(A) Schematic representation of neutrophil isolation and neutrophil extracellular trap (NET) 634 
analysis. (B) Representative images of NETs (H3Cit [green/Alexa Fluor 488], neutrophil elastase 635 
[NE] [red/Alexa Fluor 568], and nucleus [DAPI]. Scale bars: 100µM and 10µM [inset]). (C) 636 
Percentage of NETs hypercitrullinated at histone H3 (H3Cit
+
) quantified from unstimulated and 637 
ionomycin-stimulated neutrophils from control volunteers (unstimulated [n=10, one outlier 638 
removed] and stimulated [n=10, one outlier removed]), and SCD patients (unstimulated [n=10] 639 
and stimulated [n=14]). (D) Plasma levels of circulating Annexin A1 (n=5, 6 respectively) was 640 
determined in control volunteers and SCD patients. Statistical significance was determined using 641 
unpaired t test and presented as *p<0.05 vs. control volunteers. (E) Percentage of H3Cit
+
 642 
ionomycin-stimulated neutrophils from control volunteers (n=8 vehicle and n=9 AnxA1Ac2-26 pre-643 
treatment) and SCD patients (n=14 vehicle, n=9 AnxA1Ac2-26, n=10 AnxA1Ac2-26+Boc-2 and n=9 644 




p<0.01 vs. control unstimulated neutrophils.
####
p<0.0001 vs. SCD unstimulated 646 
neutrophils.
$$$$




p<0.01 vs. 647 
SCD+AnxA1Ac2-26 treated SCD neutrophils. 
φφφ




Figure 4.  AnxA1Ac2-26 dampens ERK and Akt activation in neutrophils isolated from SCD 650 
patients and activates cleaved caspase-3.  651 
A) Schematic representation of sample preparation for western blotting. Representative western 652 
blots of neutrophils from control volunteers and SCD patients for (B) ERK activation and (C) Akt 653 
activation after AnxA1Ac2-26 treatment and ionomycin stimulation. Densitometric analysis of (D) 654 
p-ERK/total ERK (n=5) and (E) p-Akt/total Akt (n=4. One outlier [defined as ≥two standard 655 
deviations] removed from control ionomycin+AnxA1Ac2-26 [30minutes]). (F+G) Percentage of 656 
H3Cit
+
 SCD-neutrophils following ionomycin stimulation (4µM, 3hours), with/without pre-657 
treatment with AnxA1Ac2-26 (30µM, 15minutes) and Akt (10µM, 30minutes), ERK (10µM, 658 
60minutes) or caspase-3 (Z-DEVD-FMK. 20µM, 45minutes) inhibitors (n=5 each group). (H) 659 
Representative immunofluorescence images of cleaved caspase-3 staining from SCD-neutrophils 660 
with/without AnxA1Ac2-26 (30μM) treatment. (I) Percentage of cleaved caspase-3
+
 neutrophils 661 
from control and SCD patients with/without AnxA1Ac2-26 treatment (n=5). Data expressed as 662 


















p<0.0001  vs. ionomycin stimulated SCD neutrophils at the 665 
corresponding time points. 
ΔΔ
p<0.01 vs. AnxA1Ac2-26 pre-treated ionomycin stimulated SCD 666 
neutrophils.  667 
 668 
Figure 5. Schematic of proposed mechanisms.  669 
Our data show (A) SCD neutrophils produce increased NETs, which are exacerbated upon 670 
stimulation (e.g. ionomycin) leading to increased phosphorylation of NET specific kinases (ERK 671 
 
31 
and Akt), which has been shown to result in histone citrullination and inhibition of apoptosis via 672 
upregulation of anti-apoptotic proteins e.g. Mcl-1
33
 (Pro-thrombotic state). Peptidylarginine 673 
deiminase 4 (PAD4)  forms a complex with intracellular calcium to catalyze histone 674 
citrullination
31
. NET stimuli activate PKC, PLC and PI3K,
33
 which in-turn activate ERK and 675 
AKT, resulting in Calcium-PAD4 complex formation, which catalyzes histone citrullination. We 676 
found (B) AnxA1Ac2-26 interacts with Fpr2/ALX suppressing ERK and Akt phosphorylation, 677 
preventing histone citrullination and enabling apoptosis by activating caspase-3 (Pro-resolving 678 
state). Abbreviations: ERK, extracellular signal-regulated kinases; Akt, protein kinase B; Mcl-1, 679 
myeloid cell leukemia protein-1; PKC, protein kinase C; PLC, Phospholipase C; PI3K, 680 
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